Phase II Success Positions Ra For Potential Blockbuster Opportunity In Myasthenia Gravis
Ra hopes to launch a Phase III program for zilucoplan next year, with a goal of bringing an alternative therapy for MG patients into competition with Alexion’s Soliris.
You may also be interested in...
As its acquisition by AstraZeneca moves toward closure, Alexion plans to file the Soliris follow-on for generalized myasthenia gravis in the US, EU and Japan. But potential competition awaits in the C5 inhibitor and FcRn antagonist classes.
The European biotech argenx has reported positive top-line results for its FcRn antagonist efgartigimod in generalized myasthenia gravis in the Phase III ADAPT study, and is planning to market the product itself in the US, Japan and major EU countries.
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.